185 related articles for article (PubMed ID: 21642870)
1. Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
Ryu JS; Shin ES; Nam HS; Yi HG; Cho JH; Kim CS; Kim HJ; Lee JE
J Thorac Oncol; 2011 Aug; 6(8):1320-9. PubMed ID: 21642870
[TBL] [Abstract][Full Text] [Related]
2. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
[TBL] [Abstract][Full Text] [Related]
3. Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Santarpia M; Ramirez JL; de Aguirre I; Garrido P; Pérez Cano M; Queralt C; Gonzalez-Larriba JL; Insa A; Provencio M; Isla D; Camps C; Blanco R; Moran T; Rosell R;
Clin Lung Cancer; 2017 Mar; 18(2):178-188.e4. PubMed ID: 27908619
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
[TBL] [Abstract][Full Text] [Related]
5. Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
Ryu JS; Kim HJ; Shin ES; Nam HS; Cho JH; Lee JE
Oncol Res; 2012; 20(1):25-30. PubMed ID: 23035362
[TBL] [Abstract][Full Text] [Related]
6. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
[TBL] [Abstract][Full Text] [Related]
7. First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Li Y; Wang LR; Chen J; Lou Y; Zhang GB
Dis Markers; 2014; 2014():960458. PubMed ID: 24591771
[TBL] [Abstract][Full Text] [Related]
8. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Xiong L; Cheng J; Gao J; Wang J; Liu X; Wang L
Clin Lung Cancer; 2013 Jul; 14(4):433-9. PubMed ID: 23522953
[TBL] [Abstract][Full Text] [Related]
10. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival.
Liu L; Wu C; Wang Y; Zhong R; Duan S; Wei S; Lin S; Zhang X; Tan W; Yu D; Nie S; Miao X; Lin D
J Thorac Oncol; 2011 Nov; 6(11):1793-800. PubMed ID: 21841506
[TBL] [Abstract][Full Text] [Related]
11. The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Nie X; Cheng G; Ai B; Zhang S
Cancer Biomark; 2013 Jan; 13(6):433-40. PubMed ID: 24595080
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
[TBL] [Abstract][Full Text] [Related]
14. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Boukovinas I; Papadaki C; Mendez P; Taron M; Mavroudis D; Koutsopoulos A; Sanchez-Ronco M; Sanchez JJ; Trypaki M; Staphopoulos E; Georgoulias V; Rosell R; Souglakos J
PLoS One; 2008; 3(11):e3695. PubMed ID: 19002265
[TBL] [Abstract][Full Text] [Related]
15. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Adjei AA; Salavaggione OE; Mandrekar SJ; Dy GK; Ziegler KL; Endo C; Molina JR; Schild SE; Adjei AA
J Thorac Oncol; 2010 Sep; 5(9):1346-53. PubMed ID: 20651609
[TBL] [Abstract][Full Text] [Related]
16. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
[TBL] [Abstract][Full Text] [Related]
18. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Ceppi P; Volante M; Novello S; Rapa I; Danenberg KD; Danenberg PV; Cambieri A; Selvaggi G; Saviozzi S; Calogero R; Papotti M; Scagliotti GV
Ann Oncol; 2006 Dec; 17(12):1818-25. PubMed ID: 16980606
[TBL] [Abstract][Full Text] [Related]
19. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
[TBL] [Abstract][Full Text] [Related]
20. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Li X; Shao M; Wang S; Zhao X; Chen H; Qian J; Song X; Wang J; Jin L; Wu J; Li Q; Bai C; Han B; Gao Z; Lu D
Tumour Biol; 2014 Nov; 35(11):11159-70. PubMed ID: 25104092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
